Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
CFO Chow Gregory K. of Sutro Biopharma Inc (NASDAQ:STRO) acquired 19,750 shares of common stock on October 15, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The insider purchase comes as InvestingPro analysis shows the stock trading below its Fair Value, with shares down nearly 9% in the past week. The shares were purchased at a weighted average price of $0.81, for a total transaction value of $15,997.
The prices paid for the shares ranged from $0.8099 to $0.8100. Following the transaction, Chow directly owns 19,750 shares of Sutro Biopharma .
In other recent news, Sutro Biopharma announced an organizational restructuring that will reduce its workforce by approximately one-third. This move aims to prioritize the company’s antibody drug conjugate (ADC) programs and is projected to extend its cash runway into at least mid-2027, aided by expected near-term milestone payments. The restructuring aligns with Sutro’s plans to announce initial clinical data from its STRO-004 ADC and initiate clinical studies for another ADC program. Additionally, Sutro Biopharma has partnered with the U.S. Food and Drug Administration to develop reference materials for ADCs, which could improve regulatory standards and analytical methods for ADC drug development.
Meanwhile, Citizens JMP analyst Reni Benjamin has reiterated a Market Perform rating on Sutro Biopharma following the company’s recent earnings announcement. Sutro reaffirmed its intention to file an Investigational New Drug application for STRO-004 in the second half of 2025. These developments reflect Sutro’s strategic focus on advancing its ADC programs and research collaborations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.